Dr. Sorensen investigates ultrasound treatment in patients with kidney stones
"This particular study comes from our human randomized trial that we hope will be the final step before FDA approval for the technology,” says Mathew D. Sorensen, MD, MS, FACS.
In this video, Mathew D. Sorensen, MD, MS, FACS, discusses the background and learning curve of ultrasonic propulsion stone treatment, from the study, “Randomized control trial of ultrasonic propulsion to facilitate clearance of chronic residual fragments,” presented recently at the 2021 American Urological Association Annual Meeting. Sorensen is an associate professor and residency program director of the department of urology at the University of Washington, Seattle, Washington.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
